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The production of cytokines by resident and non-resident
renal cells during immunoglobulin A nephropathy (IgAN)
plays a key role in the progression of renal damage. The aim
of this study was to determine if measurements of urinary
epidermal growth factor (EGF) and monocyte chemotactic
peptide-1 (MCP-1), at the time of renal biopsy, were a
predictor of end-stage renal disease (ESRD) in a cohort of 132
patients with biopsy-proven IgAN. Outcome measures were a
doubling of the baseline serum creatinine (sCr) and/or ESRD.
Patients with ratios of EGF/MCP-1 in the lowest tertile had a
significant decline in renal survival, while patients in the
highest tertile maintained 100% renal survival at 48 and 84
months of follow-up. Multivariate Cox’s regression analysis
showed that the urine EGF/MCP-1 ratio was an independent
prognostic factor and indirectly correlated with the
combined outcome. The predictive value was also measured
by the area under the receiver operating characteristic curve
(ROC). The area of the EGF/MCP-1 ratio was significantly
higher than that of EGF or MCP-1 alone, histologic grade,
creatinine clearance, or proteinuria. Our study suggests that
the urinary EGF/MCP-1 ratio may be used as a prognostic
marker of ESRD for patients with IgAN.
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Immunoglobulin A nephropathy (IgAN) is an immunocom-
plex-mediated glomerulonephritis characterized by the pre-
sence of IgA deposits in the mesangial area.1 It is the most
common primary glomerulonephritis (25–50% of diagnosed
renal biopsies), and although initially thought to represent a
benign condition, it is now recognized that IgAN leads to
end-stage renal disease (ESRD) in a substantial proportion of
patients within 10–20 years from the time of renal biopsy.2
The clinical course is extremely variable ranging from
persistent asymptomatic microscopic hematuria to rapidly
progressive renal failure. The severity of histologic lesions, the
presence of impaired renal function, arterial hypertension,
and the degree of proteinuria at the time of renal biopsy are
all well-known prognostic factors for the development of
ESRD in IgAN patients.3–6
Progressive renal disease, regardless of the initiating insult,
is characterized by glomerulosclerosis, tubulointerstitial
fibrosis, and vascular sclerosis. The importance of the
tubulointerstitial compartment in the progression of renal
damage is supported by the evidence that the severity of
tubulointerstitial changes, including tubular atrophy, inter-
stitial cell infiltration, and fibrosis, is significantly correlated
with the decline in renal function.7
There is an increasing body of evidence that the
chemokine monocyte chemotactic peptide-1 (MCP-1), which
promotes monocyte-specific chemotaxis, plays a major role
in the progression of renal disease, both in animal models of
renal damage and in different types of human renal disease.8
Protein overload of proximal tubular epithelial cells results,
in vitro and in vivo, in the increased tubular expression of
MCP-1, which promotes the recruitment of inflammatory
cells into the interstitium.9,10 The extent of macrophage
infiltration in the peritubular space is strongly correlated with
the development of progressive interstitial fibrosis. Indeed,
infiltrating macrophages represent both a source and a
reservoir of profibrotic factors, including transforming
growth factor-b (TGF-b), endothelin-1, and tumor necrosis
factor-a (TNF-a), which induce matrix synthesis by resident
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parenchymal cells. They can also release inhibitors of matrix-
degrading proteases, such as tissue inhibitor of metallopro-
teinase-1 and plasminogen activator inhibitor-1.11 Our group
has previously shown that MCP-1 urine excretion is
significantly correlated with its renal expression as well as
with the extent of interstitial inflammatory infiltrate in
several renal diseases.12 On the other hand, epidermal growth
factor (EGF), a 53-amino-acid peptide, produced by the
ascending portion of Henle’s loop and by the distal
convoluted tubule, seems to modulate tissue response to
injury in kidneys with tubulointerstitial damage. In this
setting, we reported a decrease in the renal expression and
urinary excretion of EGF.13 On this basis, EGF urinary
excretion has been suggested as a marker of tubular trophism.
Our group demonstrated that the urinary levels of EGF
inversely correlated with the extent of tubulointerstitial
damage in IgAN.14
The aim of our study was to evaluate the prognostic value
of the urinary excretion of EGF and MCP-1 ratio, at the time
of renal biopsy, in predicting the progression of renal disease
in a cohort of IgAN patients.
RESULTS
A cohort of 132 consecutive subjects was diagnosed as IgAN
(91 men and 41 women). The general clinical characteristics
of all patients are listed in Table 1. Mean age at renal biopsy
was 31.6711.4 years. Microhematuria at onset was present
in 63/132 (48%) and recurrent macrohematuria (MH) in
69/132 (52%) patients. Out of 132 patients, 48 (36.4%)
patients were hypertensive at renal biopsy. At baseline, mean
serum creatinine (sCr) was 1.270.7 mg per 100 ml, estimated
creatinine clearance (eCrCl) 95.3729.5 ml min1, and mean
proteinuria (uPr) was 1.371.1 g day1. Renal biopsy showed
mild lesions (grades I–II) in 29/132 (22%) patients, moderate
lesions (grade III) in 78/132 (59%), and severe lesions (grades
IV–V) in 25/132 (19%). Ninety-eight patients, 74% of the
total cohort, were treated with angiotensin converting
enzyme inhibitors and/or angiotensin II receptor blockers
in any period of the follow-up.
Urinary cytokine measurement
We evaluated EGF, MCP-1, and their ratio in the urine of
all IgAN patients at the time of renal biopsy. The urinary
levels of EGF, MCP-1, and EGF/MCP-1 ratio expressed as
ng/mg uCr were 18.3 (8.03–44.5), 0.42 (0.2–0.7), and 48.9
(21.1–96.1), respectively.
Urinary EGF/MCP-1 ratio was significantly lower in 25
IgAN patients with severe histologic lesions compared to 78
subjects with moderate and 29 with mild histologic lesions
(median EGF/MCP-1 (25th–75th percentile): severe, 8.9
(3.9–30.2); moderate, 43.0 (23.7–81.5); mild, 98.2
(54.6–152.2); severe vs moderate and moderate vs mild,
P¼ 0.001; severe vs mild, Po0.0001) (Figure 1).
There was a significant direct correlation between
EGF/MCP-1 ratio and eCrCl (R¼ 0.39, Po0.0001) and a
significant inverse correlation between EGF/MCP-1 ratio and
uPr (R¼ 0.35, Po0.0001). The EGF levels correlated
significantly with eCrCl (R¼ 0.41, Po0.0001) and not with
uPr (R¼ 0.08, P¼ 0.38), conversely, the MCP-1 levels
correlated significantly with uPr (R¼ 0.39, Po0.0001) and
not with eCrCl (R¼ 0.05, P¼ 0.58).
The EGF/MCP-1 ratios corresponding to the first, second
and third tertiles were 29.2, 70.4, 366.6, respectively. Baseline
mean age, gender, proportion of patients with macrohema-
turia, and follow-up duration did not show statistically
Table 1 | Demographic and clinical characteristics of 132 IgAN
patients
No. of patients 132
Gender (male) 91 (69%)
Age at renal biopsy (years) 31.6711.4
Macrohematuria (yes) 69 (52%)
Hypertension (yes) 48 (36%)
Serum creatinine (mg per 100 ml) 1.270.7
Estimated creatinine clearance (ml min1) 95.3729.5
Proteinuria (g per 24 h) 1.371.1
EGF (ng/mg uCr) 18.35 (8.03–44.5)
MCP-1 (ng/mg uCr) 0.42 (0.22–0.74)
EGF/MCP-1 48.9 (21.1–96.1)
Renal lesions
Mild (grades I–II) 29 (22%)
Moderate (grade III) 78 (59%)
Severe (grades IVV) 25 (19%)
Therapy with ACE-I and/or ARB 98 (74%)
Follow-up (months) 54 (35–84)
ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor
blockers; EGF, epidermal growth factor; IgAN, immunoglobulin A nephropathy;
MCP-1, monocyte chemotactic peptide-1.
Data are expressed as mean7s.d. or median and IQR, absolute frequency or
percentage.
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Figure 1 | Histologic grade and urinary values of EGF/MCP-1 ratio.
The EGF/MCP-1 ratio was significantly different comparing mild vs
moderate (P¼ 0.001) and severe (Po0.0001) histologic lesions and
comparing moderate vs severe (Po0.001) histologic lesions (line
crossing boxes show the median values; boxes show the interquartile
range; whiskers show the largest and smallest observed values that
are less than 1.5 box lengths from the 25th and 75th percentile; and
the outlier represents a case with a value between 1.5 and 3 box
lengths from the upper and lower edge of the box).
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significant differences in the three groups. Instead, sCr, uPr,
eCrCl, histologic grade, and the prevalence of arterial
hypertension at renal biopsy showed statistically significant
differences among the three tertiles. There were no
statistically significant differences in the proportion of
patients treated with angiotensin converting enzyme inhibi-
tors and/or angiotensin II receptor blockers in the three
groups (Table 2).
Renal survival
Twenty-seven events of the combined outcome occurred in a
median follow-up of 54 (35–84) months from the renal
biopsy, 24 in the first, 3 in the second, and none in the third
tertile, respectively. Patients with the lowest EGF/MCP-1
tertile showed a renal survival of 73 and 36%, at 48 and 84
months of follow-up, respectively. Patients within the second
tertile showed a renal survival of 94% at 48 and 84 months of
follow-up, and those in the highest EGF/MCP-1 tertile
showed a renal survival of 100% during the whole follow-up
period (log-rank test, Po0.0001) (Figure 2).
Univariate analysis showed that baseline eCrCl, uPr,
histologic grade, hypertension, EGF, and EGF/MCP-1 ratio
were significantly associated with the outcome. MCP-1
showed only a weak association with the outcome, while no
association was demonstrated for gender and age at renal
biopsy. Unadjusted risk estimates of different risk factors for
the combined outcomes are reported in Tables 3 and 4.
Multivariate Cox’s regression analysis showed that EGF,
MCP-1, and EGF/MCP-1 ratio were independently associated
with the combined outcome, after the adjustment for age and
gender (data not shown), but also after the adjustment for
eCrCl, uPr, histologic grade, and hypertension at renal biopsy
(model 2) (Table 4). No interaction between the exposure
variables and histologic grade, uPr, and/or eCrCl was found;
the test for interaction did not modify the risk estimate of the
outcome.
The ability of the EGF/MCP-1 ratio to predict the
combined outcome was investigated by means of a receiver
operating characteristic curve (ROC) analysis. To support the
usefulness of EGF/MCP-1 ratio (rather than the two single
measures), we performed an ROC analysis in which EGF,
MCP-1, and EGF/MCP-1 ratio were compared. The areas
under the curve (AUCs) (95% confidence interval (CI)) were
0.83 (0.76–0.89), 0.57 (0.49–0.66), and 0.91 (0.85–0.96),
respectively. The differences between the areas were statisti-
cally significant between EGF and the ratio (P¼ 0.01) and
between MCP-1 and the ratio (Po0.001), demonstrating a
better prediction capacity for the ratio (data shown in Figure
3a). Then, we compared our biomarker with the other
covariates at baseline; the EGF/MCP-1 ratio showed an AUC
and a 95% CI of 0.91 (0.84–0.95), compared to 0.76
(0.65–0.88) of eCrCl, 0.75 (0.63–0.88) of histologic grade,
Table 2 | Demographic and clinical characteristics of 132 IgAN patients divided into three tertile groups of EGF/MCP-1 levels
Tertiles
Characteristics First Second Third P-value
No. of patients 44 44 44
Age (years) 32.5 (11.2) 32.3 (11.8) 30.0 (11.4) 0.49
Gender (male) 33 (75%) 30 (68%) 28 (64%) 0.51
Macrohematuria (yes) 26 (59%) 22 (50%) 21 (48%) 0.52
Hypertension (yes) 22 (50%) 16 (36%) 10 (23%) 0.03
Serum creatinine (mg per 100 ml) 1.6 (0.9) 1.0 (0.2) 0.9 (0.2) o0.0001
Urinary protein excretion (mg day1) 1.8 (1.3) 1.1 (0.9) 1.0 (0.8) 0.003
Estimated creatinine clearance (ml min1) 75.1 (30.2) 102.2 (23.8) 109.1 (23.0) o0.0001
Histologic grade (mild/moderate/severe) (1/25/18) (10/31/3) (18/22/4) o0.0001
Therapy with ACE-I and/or ARB (yes) 34 (77%) 30 (68%) 34 (79%) 0.35
Follow-up duration (months) 58.3 (46.2) 51.0 (32.2) 59.6 (32.3) 0.11
ACE-I, angiotensin converting enzyme inhibitors; ANOVA, analysis of variance; ARB, angiotensin II receptor blockers; EGF, epidermal growth factor; IgAN, immunoglobulin A
nephropathy; MCP-1, monocyte chemotactic peptide-1.
Data are expressed as mean7s.d., absolute or percentage frequency; comparison between groups was made by one-way ANOVA, unpaired Student’s t-test, or w2 test.
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Figure 2 | Kaplan–Meier analysis of renal survival in the total
cohort of patients divided into the tertiles of EGF/MCP-1 ratio.
The number of events was significantly higher in the first tertile
(log-rank test, w2¼ 43.1, P¼ 0.0001). The combined outcome was
ESRD and/or doubling of sCr. Patients at risk were the number of
cases in observation at each time.
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and 0.68 (0.56–0.81) of uPr. EGF/MCP-1 ratio reached the
highest sensitivity and specificity in the prediction of the
combined outcome (Figure 3b). The cutoff values for EGF/
MCP-1 ratio, eCrCl, and uPr were 23.2 (sensitivity 88.9%;
specificity 86.4%), 88.8 ml min1 (sensitivity 76.9%; specifi-
city 71.1%), and 0.71 g day1 (sensitivity 77.8%; specificity
61.0%), respectively. Moreover, we explored the differences in
the AUCs between EGF/MCP-1 ratio and all the other risk
factors, and found statistically significant results between
EGF/MCP-1 ratio and eCrCl (P¼ 0.002), EGF/MCP-1 ratio
and uPr (P¼ 0.004), and between EGF/MCP-1 ratio and
histologic grade (P¼ 0.005). No statistically significant
results were demonstrated between eCrCl and uPr, eCrCl
and histologic grade, and uPr and histologic grade.
Finally, to confirm our results of survival analysis, we
explored the association between EGF/MCP-1 ratio and the
rate of loss of eGFR. First, we correlated EGF/MCP-1 ratio
with eCrCl slope, demonstrating a statistically significant
direct correlation (R¼ 0.24, P¼ 0.0091). Then, we performed
a multiple regression analysis, adjusting for the other
covariates at baseline (eCrCl, uPr, and histologic grade), also
demonstrating in this further analysis that EGF/MCP-1 ratio
significantly correlated with the eCrCl slope with a P¼ 0.017.
DISCUSSION
Urinary cytokines seem to play a key role in the progression
of renal damage in IgAN. EGF is the main trophic factor for
tubular cells, and it has also been shown to modulate tissue
response to injury.13 Kidneys with tubulointerstitial damage
exhibit a decreased EGF renal synthesis and urinary
excretion.14 Conversely, MCP-1 plays a major role in the
progression of renal disease, both in animal models and in
different types of human renal diseases, including IgAN.15,16
In lupus nephritis, urinary levels of MCP-1 excretion
significantly predicted both renal flares and the lack of
response to therapy.17 A recent study conducted in 215
patients with different nephropathies showed a correlation
between urinary levels of MCP-1, interstitial monocyte
infiltration, and albumin/creatinine ratio. In this study,
urinary MCP-1 independently predicted renal survival.18 In
previous studies, we demonstrated in IgAN patients a
correlation between urinary levels of MCP-1, monocytic
infiltration, and tubulointerstitial damage,12 and between
urinary levels of EGF and the degree of histological lesions.13
This study is the first prospective clinical study evaluating
the prognostic significance of urinary EGF/MCP-1 ratio on
renal survival conducted in a cohort of incident IgAN
patients with a long-term follow-up and comparing it with
established risk factors for ESRD.
In the first part of the study, we demonstrated, as
expected, a significant reduction of the EGF/MCP-1 ratio in
the urine of patients with more severe histologic lesions at the
time of renal biopsy. Then, we demonstrated a significant
correlation between our biomarker, eCrCl, and uPr. Finally,
we assessed the independent effect of EGF/MCP-1 ratio on
adverse outcome. Not surprisingly, in our cohort of patients,
we found that the severity of the histologic lesions, the
amount of daily proteinuria, the presence of impaired renal
function, and hypertension at the time of renal biopsy were
all prognostic factors of the combined outcome at the
univariate analysis, as demonstrated also in previous cohort
studies.3–6 The main finding in the multivariate analysis was
Table 3 | Unadjusted risk estimates by Cox’s proportional hazard models for the combined outcome in 132 IgAN patients
Risk factor
Unit of increase or
reference category
Unadjusted risk
(HR) (95% CI) P-value
Estimated creatinine clearance (ml min1) 1 0.97 (0.96–0.98) o0.0001
Histologic lesions grade Mild 6.50 (3.26–12.96) o0.0001
Proteinuria at renal biopsy (g per 24 h) 1 1.68 (1.36–2.08) o0.0001
Hypertension at renal biopsy 0=no; 1=yes 0.31 (0.14–0.67) 0.003
Gender 0=male; 1=female 0.50 (0.19–1.34) 0.17
Age (years) 1 1.01 (0.98–1.04) 0.50
Onset type 0=mH; 1=MH 1.30 (0.60–2.82) 0.50
Therapy with ACE-I and/or ARB 0=no; 1=yes 0.76 (0.32–1.81) 0.54
ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; CI, confidence interval; EGF, epidermal growth factor; HR, hazard ratio; IgAN,
immunoglobulin A nephropathy; MCP-1, monocyte chemotactic peptide-1; mH, microhematuria; MH, macrohematuria.
Data are expressed as unadjusted HR and 95% CIs.
Table 4 | EGF, MCP-1, and the EGF/MCP-1 ratio risk estimates by Cox’s proportional hazard models for the combined outcome
in 132 IgAN patients
EGF/MCP-1 ratio EGF (ng/mg uCr) MCP-1 (ng/mg uCr)
Models HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Unadjusted (1) 0.93 (0.90–0.96) o0.0001 0.95 (0.92–0.98) 0.002 1.25 (0.98–1.59) 0.067
Adjusted (2) 0.94 (0.91–0.98) 0.002 0.95 (0.92–0.98) 0.002 1.35 (1.04–1.80) 0.024
CI, confidence interval; eCrCl; estimated creatinine clearance; EGF, epidermal growth factor; HR, hazard ratio; IgAN, immunoglobulin A nephropathy; MCP-1, monocyte
chemotactic peptide-1; uPr, mean proteinuria.
Model 1 (unadjusted HR); model 2 (adjusted for eCrCl, uPr, hypertension, and histologic grade).
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that the EGF/MCP-1 ratio, measured at the time of renal
biopsy, independently predicted the combined outcome.
Although we demonstrated that the EGF/MCP-1 ratio was
an independent risk factor for adverse outcome in our study
population, this did not necessarily imply that it was able to
accurately distinguish between patients with good prognosis
and those with poor prognosis. For this reason, we also
calculated the predictive value of EGF/MCP-1 ratio, of EGF
and MCP-1 single measurements, and of the other prognostic
factors by means of an ROC analysis. EGF/MCP-1 ratio
improved the sensitivity and the specificity in predicting the
adverse outcome compared to the two cytokines alone and to
the other risk factors, as shown by the AUC in the ROC
analysis (Figure 3a and b).
The EGF/MCP-1 ratio also significantly correlated with
the rate of loss of eGFR in the univariate and multivariate
analyses. These findings, confirmed in different multivariate
approaches, show a strong association of the EGF/MCP-1
ratio and different outcome measures.
Selection bias was avoided in our study, by including all
consecutive patients receiving a histologic diagnosis of IgAN
in our renal unit and in a predefined period of enrollment (5
years). The demographic and clinical characteristics of the
study population were comparable to those of our historic
IgAN database, which includes more than 400 patients.19
However, this study has some limitations. The single-
center nature of the report may have an impact on its
external validity. In addition, renal survival in IgAN could be
influenced by different therapeutic strategies. Considering
that most of our patients received angiotensin converting
enzyme inhibitors and/or angiotensin II receptor blockers
during the follow-up, there were no statistically significant
differences in the proportion of patients treated and those
untreated in the three tertile groups of the EGF/MCP-1 ratio.
For this reason, we do not think that therapy could have
influenced our results. Another limitation could be the single
measurement of cytokines at baseline and not during the
follow-up, but this was the first time when we used the Renal
Progression Kit, and after having obtained these results, we
are planning to validate the method in a larger cohort of
patients, with repeated measures of urine cytokines.
In conclusion, this study suggests that urinary EGF/MCP-
1 ratio may be a useful and reliable marker of progression in
IgAN. During the long-term follow-up of IgAN patients, the
major difficulties are represented by the evaluation of disease
progression with the routine laboratory parameters, which
have great limitations in terms of sensitivity and specificity in
monitoring the intrarenal changes. In these patients, it is
sometimes necessary to repeat the renal biopsy, but this being
an invasive procedure, a cost–benefit analysis is mandatory.
In these particular cases, the EGF/MCP-1 ratio measurement
might help us to predict the progressive deterioration of renal
function, avoiding more invasive procedures when not
necessary. These results could be used to prospectively
identify high-risk patients who may benefit from a closer
follow-up and a more aggressive therapeutic approach.
Further prospective studies in a larger population of patients
are warranted to support our hypothesis.
MATERIALS AND METHODS
Patients
This is a prospective cohort study. We enrolled all consecutive
patients who underwent renal biopsy in our Renal Unit and received
a diagnosis of IgAN from January 1995 to December 2000. The
planned follow-up was to December 2005.
The included patients met the following criteria: (1) dominant or
codominant deposition of mesangial IgA by immunofluorescence
microscopy; (2) no signs or symptoms of secondary IgA deposition,
including systemic lupus erythematosus, Scho¨nlein–Henoch pur-
pura, and liver disease. We excluded all those patients receiving
corticosteroids or immunosuppressive therapy. All renal biopsies
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Figure 3 | ROC analysis. (a) ROC analysis of the predictive value for
adverse outcomes of EGF, MCP-1, and EGF/MCP-1 ratio. The AUC of
EGF/MCP-1 was 0.91 (95% CI: 0.84–0.95), showing a better capacity of
discrimination compared to EGF (0.83, 95% CI: 0.76–0.89; P¼ 0.01)
and MCP-1 (0.57, 95% CI: 0.49–0.66; Po0.001) alone. (b) ROC analysis
of the predictive value for adverse outcomes of EGF/MCP-1 ratio and
other risk factors. The AUC of EGF/MCP-1 ratio was significantly
higher than that of eCrCl (0.76 (0.65–0.88); P¼ 0.002), of histologic
grade (0.75 (0.63–0.88); P¼ 0.005), and of uPr (0.68 (0.56–0.81);
P¼ 0.004).
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were performed at least 30 days after episodes of macroscopic
hematuria, after signed informed consent.
Serum creatinine and daily proteinuria (uPr) were assessed at
baseline and over time. eCrCl was calculated with Cockcroft and
Gault formula.20 Patients were considered hypertensive if their
arterial blood pressure was higher than the level recommended by
the VI Joint National Committee Guidelines21 or if levels less than
140–90 mm Hg were reached using antihypertensive drugs. Each
patient was evaluated clinically and with laboratory tests every 3–6
months. Outcome measures were doubling of baseline sCr and/or
ESRD (defined as the need for regular dialysis treatment or renal
transplant). The study was performed according to recommenda-
tions outlined in the Declaration of Helsinki Principles (IV
Adaptation).
Renal biopsies
Renal specimens, obtained by needle-core biopsies (14 or 16 gauge)
performed under ultrasonographic guidance, were fixed in 4%
formaldehyde, paraffin-embedded, and then processed for routine
light microscopy stainings (hematoxylin–eosin, periodic acid-Schiff,
silver methenamine, and Masson’s trichrome). The frozen tissue was
processed for routine immunofluorescence microscopy with antisera
for IgG, IgA, IgM, C3, C1q, and fibrinogen (The Binding Site,
Birmingham, UK).
On the basis of the severity of glomerular, tubular, and interstitial
lesions, all renal biopsies were scored in five grades according to
Lee’s classification and grouped into mild lesions (grades I–II),
moderate lesions (grades III), and severe lesions (grades IV–V).22
Urinary cytokine measurement
At the time of renal biopsy, morning urine samples were collected
from each patient to evaluate urinary EGF and MCP-1 excretion.
The urine samples were centrifuged at 600 g for 5 min and frozen at
201C until tested. None of the patients had urinary tract infections
at the time of the study. Quantitative assay of EGF and MCP-1 levels
in urine samples was performed using the Renal Progression Kit
(Apulia Biotech s.c.r.l., Valenzano (Bari), Italy). This is a direct
sandwich enzyme-linked immunosorbent assay (ELISA) kit specific
for the urine samples in which one-half of the polystyrene 96-well
microtiter plate was coated with monoclonal anti-human MCP-1
antibody (Anogen, Mississauga, Ontario, Canada) and the other half
with monoclonal anti-human EGF antibody (Anogen). After
incubation with urine, the second monoclonal antibody (Anogen)
conjugated with horseradish peroxidase (HRP) was added to the
respective wells and the enzymatic reaction was detected in an
automatic microplate photometer (Programmable MTP reader DV
990BV6; Gio. DeVita E C, Rome, Italy). The EGF and MCP-1
concentrations of the unknown urine samples were determined by
interpolation into a standard curve developed with known amounts
of recombinant human EGF and MCP-1 proteins (R&D Systems
Inc., Minneapolis, MN, USA), and expressed in ng ml1. The lower
detection limit was 0.03 ng ml1 for EGF and 0.42 ng ml1 for MCP-
1. The measurement of each cytokine was normalized for uCr, and
then we used the ratio of the two normalized measurements as a
marker of renal damage. The intra- and interassay coefficients of
variation were approximately 7 and 8% for EGF and 5 and 8% for
MCP-1, respectively.
Epidermal growth factor and MCP-1 stability in the urine was
tested by measuring the concentrations of the two cytokines at the
time of collection and after 2 months, and we did not observe any
significant difference between the two measurements. Moreover, we
measured urine EGF/MCP-1 ratio in four normal subjects over a
period of 4 consecutive days, demonstrating a daily variability of
7.8%. The evaluation of EGF and MCP-1 urine excretion was
performed by an independent researcher unaware of patient’s
clinical history.
Statistical analysis
Continuous data were analyzed descriptively by using mean7s.d. or
median and interquartile range. Categorical data were described as
absolute frequencies and percentages.
Baseline characteristics of individuals affected by IgAN were
compared by one-way analysis of variance, Kruskal–Wallis test,
unpaired Student’s t-test, and Mann–Whitney U-test as appropriate
for continuous data, and by the w2 statistic for categorical data. To
evaluate the differences between patients, the values of urinary EGF/
MCP-1 ratio were grouped into tertiles.
Linear regression analysis was performed to determine the
correlation between different levels of urinary EGF, MCP-1, and the
EGF/MCP-1 ratio and the renal function expressed as eCrCl. We also
investigated the correlation between these cytokines and the degree
of uPr at the time of renal biopsy. Finally, the correlation between
the EGF/MCP-1 ratio and the loss of GFR expressed as eCrCl slope
was explored by simple linear and a multivariate regression analysis,
the last adjusting for other risk factors.
Cumulative renal survival from the time of renal biopsy was
analyzed by Kaplan–Meier curves for censored data, using as
outcome measure the combined end point of doubling sCr
and/or ESRD; differences between groups were compared by the
log-rank test.
The association between the combined outcome and potential
risk factors was examined using univariate Cox’s regression
proportional hazard method. Predictors univariately associated with
outcome (Po0.10) were included in a multivariate Cox’s regression
model, and the goodness of fit was estimated. We used all predictors
as continuous variables. Risk estimates were presented as unadjusted
and adjusted hazard ratios, and their 95% CIs were calculated by an
estimated regression coefficient in the Cox’s regression analysis.
Since all covariates used in the final model were strongly
correlated with the exposure variable, to address the possibility that
they could be potential confounders, we tested for the significance of
interactions between the EGF/MCP-1 ratio and the covariates
included in the multivariable model.
The problem of missing values was resolved by carrying out a
complete case analysis; data were missing in less than 5% of patients.
The predictive value of the known risk factors EGF, MCP-1, and
the EGF/MCP-1 ratio, used as test variables in predicting the
combined end point was investigated by the area under the ROC,
using each parameter as a continuous variable.
All analyses were performed using SPSS for Windows, release
12.0; results were considered statistically significant when two-tailed
P-values were p0.05.
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